Company Description
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.
The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.
The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers.
The company is headquartered in Toronto, Canada.
| Country | Canada |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 50 |
| CEO | Douglas L. Drysdale |
Contact Details
Address: 100 King Street West, Suite 5600 Toronto, A6 M5X 1C9 Ontario, Canada | |
| Phone | (908) 764-8385 |
| Website | cybin.com |
Stock Details
| Ticker Symbol | CYBN |
| Exchange | NYSEAMERICAN |
| Fiscal Year | April - March |
| Reporting Currency | CAD |
| CIK Code | 0001833141 |
| CUSIP Number | 23256X100 |
| ISIN Number | CA23256X1006 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Douglas L. Drysdale | Chief Executive Officer |
| Eric So L.L.B. | Co-Founder, President and Executive Chairman |
| Paul Glavine | Co-Founder, Chief Growth Officer and Director |
| Greg Cavers | Chief Financial Officer |
| Aaron Bartlone | Chief Operating Officer |
| John Kanakis | Co-Founder |
| Dr. Alex L. Nivorozhkin Ph.D. | Chief Scientific Officer |
| Lori Challenger | Chief Compliance, Ethics and Administrative Officer |
| Gabriel Fahel | Chief Legal Officer and Corporate Secretary |
| Sara Brittany Somerset | Chief Communications Officers |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 5, 2024 | 6-K | Report of foreign issuer |
| Jun 27, 2024 | 6-K/A | Filing |
| Jun 26, 2024 | 6-K | Report of foreign issuer |
| Jun 26, 2024 | 40-F | Filing |
| Jun 20, 2024 | 6-K | Report of foreign issuer |
| Jun 11, 2024 | 6-K | Report of foreign issuer |
| May 29, 2024 | 6-K | Report of foreign issuer |
| May 14, 2024 | 6-K | Report of foreign issuer |
| May 6, 2024 | 6-K | Report of foreign issuer |
| Apr 25, 2024 | 6-K | Report of foreign issuer |